The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to buy a great stock on the cheap. The post At a bargain-basement valuation now, ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData. Part of the market’s potential is its increased safety over immunotherapies, ...

Three more fake batches of the cancer immunotherapy have been encountered in Iran and Türkiye, warns the agency.

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and ...